SEC Form 4 · accession 0001662252-16-000301
Xenetic Biosciences, Inc. · XBIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Edward J. Benz Jr.
Director
Period of report
Dec 20, 2016
Accepted (ET)
Dec 23, 2016 · 2:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001534525
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1 | $3.49 | Dec 20, 2016 | A | 6,250 | A | Feb 21, 2017 | Nov 21, 2026 | Common Stock | 6,250 | 6,250 | D |
| Stock OptionF1 | $3.49 | Dec 20, 2016 | A | 6,250 | A | May 21, 2017 | Nov 21, 2026 | Common Stock | 6,250 | 12,500 | D |
| Stock OptionF1 | $3.49 | Dec 20, 2016 | A | 6,250 | A | Aug 21, 2017 | Nov 21, 2026 | Common Stock | 6,250 | 18,750 | D |
| Stock OptionF1 | $3.49 | Dec 20, 2016 | A | 6,250 | A | Nov 21, 2017 | Nov 21, 2026 | Common Stock | 6,250 | 25,000 | D |
Explanation of responses
- F1On December 20, 2016 the Issuer approved the issuance of a Stock Option Grant to the Reporting Owner under its 2014 Equity Incentive Plan (the "Plan"). The Reporting Owner has the right to purchase 25,000 shares of common stock of the Issuer under the Plan at an exercise price based on the closing price on December 19, 2016 of $3.49. The Option vests one-quarter of the total grant for each quarter of service over the twelve-month period commencing on the grant date.